121 research outputs found
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma. Methods: In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0–2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received. Patients were randomly assigned (1:1) by an interactive web-response system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone. Randomisation was stratified by number of previous lines of therapy and International Staging System disease stage. All patients received oral pomalidomide (4 mg, once daily on days 1–21) and oral dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle. The daratumumab plus pomalidomide and dexamethasone group received daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3–6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT03180736. Findings: Between June 22, 2017, and June 13, 2019, 304 patients (median age 67 years [IQR 60–72]; 161 [53%] men and 143 [47%] women) were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n=151) or the pomalidomide and dexamethasone group (n=153). At a median follow-up of 16·9 months (IQR 14·4–20·6), the daratumumab plus pomalidomide and dexamethasone group showed improved progression-free survival compared with the pomalidomide and dexamethasone group (median 12·4 months [95% CI 8·3–19·3] vs 6·9 months [5·5–9·3]; hazard ratio 0·63 [95% CI 0·47–0·85], two-sided p=0·0018). The most common grade 3 or 4 adverse events were neutropenia (101 [68%] of 149 patients in the daratumumab plus pomalidomide and dexamethasone group vs 76 [51%] of 150 patients in the pomalidomide and dexamethasone group), anaemia (25 [17%] vs 32 [21%]), and thrombocytopenia (26 [17%] vs 27 [18%]). Serious adverse events occurred in 75 (50%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group versus 59 (39%) of 150 patients in the pomalidomide and dexamethasone group; pneumonia (23 [15%] vs 12 [8%] patients) and lower respiratory tract infection (18 [12%] vs 14 [9%]) were most common. Treatment-emergent deaths were reported in 11 (7%) patients in the daratumumab plus pomalidomide and dexamethasone group versus 11 (7%) patients in the pomalidomide and dexamethasone group. Interpretation: Among patients with relapsed or refractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death versus pomalidomide and dexamethasone alone and could be considered a new treatment option in this setting. Funding: European Myeloma Network and Janssen Research and Development.European Myeloma Network and Janssen Research and Development
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.The APOLLO study was sponsored by the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC. Medical writing and editorial support were provided by Justine Lempart, PhD, and Linda V. Wychowski, PhD, of Eloquent Scientific Solutions and were funded by Janssen Global Services, LL
Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma
Anemia is a common side-effect of patients with multiple myeloma (MM)
and lymphoma. The etiology is complex, but the main cause is the
underlying mechanism of anemia of chronic disease, which is
characterized among others, by impairment of iron metabolism and
consequently iron restricted erythropoiesis (IRE), resulting from the
up-regulation of the iron distributing regulator, hepcidin.
Erythopoiesis-stimulating agents (ESAs) have been the standard of care
since early 90’s offering high response rates and improving the quality
of life of the patients. However, the role of ESAs in the treatment of
cancer-related anemia has been questioned recently, due to the growing
evidence which support that ESAs may be associated with increased risk
for thrombosis and may have a detrimental impact on patients’ survival.
Under the light of the recent considerations, the place of ESAs in the
management of cancer-related anemia has been reassigned. Regarding the
management of anemia in MM or lymphoma, the updated American Society of
Clinical Oncology/American Society of Hematology (ASCO/ASH) 2007
clinical practice guidelines on the use of ESAs in cancer-related
anemia, recommended that ESAs should be preferably omitted in patients
planned to receive chemotherapy and applied in case that anemia does not
improve over treatment. The quest for reliable predictors for response
to ESAs and for indicators of IRE which plays a major etiological role
for the development of anemia of cancer still remains an open issue. In
the current review we present an update on ESAs use in anemia of MM and
lymphoma. (C) 2009 Elsevier Ltd. All rights reserved
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
Background: Receptor activator of NF-kappa B ligand (RANKL) binds to
RANK on the surface of osteoclast precursors and enhances their
differentiation, survival and fusion, activates mature osteoclasts and
inhibits their apoptosis. Osteoprotegerin (OPG) is the decoy receptor of
RANKL. Disruption of the RANK/RANKL/OPG axis is implicated in bone
metastases. Objective/methods: A review of the role of RANKL signaling
in bone development and the rationale for targeting RANKL in treatment
of bone metastases and myeloma bone disease. Results/conclusions: In
preclinical models of solid tumors and myeloma, RANKL inhibition reduced
osteoclast numbers and subsequent bone resorption, prevented development
of osteolytic lesions and decreased tumor burden. Preliminary clinical
studies with denosumab, an anti-RANKL fully human monoclonal antibody,
in patients with solid tumors with bone metastases and myeloma showed
that targeting RANKL reduces osteoclastogenesis, bone resorption markers
and skeletal-related events, supporting further study of this molecule
and others with anti-RANKL activity
- …